Technology Bundle ID
TAB-3515

Use Of p21-Activated Kinases (PAK) Inhibitors for the Treatment of CNS Disorders and Cancer

Applications
Linked ID
E-234-2012-0
Lead Inventors
David Campbell (aFRAXis, Inc.)
Co-Inventors
John McKew (NCATS)
Mark Behnke (NCATS)
Min Shen (NCATS)
Na Yang (NCATS)
Seameen Dehdashti (NCATS)
Sergio Duron (aFRAXis, Inc.)
Wei Zheng (NCATS)
Wenwei Huang (NCATS)
ICs
This technology includes the compounds, compositions, and methods for treating CNS disorders and cancer with an inhibitor of a p21-activated kinase (PAK). PAK activation is shown to play a key role in spine morphogenesis, and attenuation of PAK can reduce, prevent or reverse defects in spine morphogenesis leading to improvements in synaptic function, cognition, and/or behavior. This could be used to treat a wide variety of CNS disorders such as schizophrenia, Alzheimer’s, Parkinson’s Disease, depression, bipolar, and many others. Additionally, the PAK family of serine/threonine kinases plays a pivotal role in physiological processes including motility, survival, mitosis, transcription, and translation. PAKs are widely expressed in a variety of tissues and activated in multiple cancer types (i.e., breast, skin, lung, colon, brain, prostate, kidney, liver). PAK inhibitors can be administered to inhibit aberrant cellular proliferation as a cancer therapy.
Commercial Applications
Further clinical work with these PAK inhibitors could establish them as a treatment of CNS disorders and cancer.
Competitive Advantages
PAK inhibitors have a wide range of potential therapeutic uses with a large market size.

Request More Info

Licensing Contact: